Lyrus

World Cancer Day: Innovating for a Cancer-Free Future
At Lyrus, a trusted CDMO partner, we're harnessing advanced NDDS and platform technologies to develop targeted, controlled-release formulations for oncology therapies. Our world-class R&D team, backed by cGMP-compliant analytical development and regulatory expertise (eCTD/ANDA), delivers end-to-end solutions—from formulation to pilot scale—for regulated markets like US, Europe, and Australia.
Join us in raising awareness and accelerating breakthroughs. Let's collaborate to transform patient outcomes.

On January 30, World Neglected Tropical Diseases(NTD) Day, we shine a light on the 1.6 billion people worldwide affected by NTDs—diseases that thrive in resource-limited settings but steal millions of healthy years annually.
At Lyrus, we're bridging the access gap through strategic global alliances, portable drug delivery solutions, and cutting-edge NDDS platforms. Our partnerships with international health organizations enable scalable formulations that withstand harsh logistics—from humid tropics to remote villages—ensuring therapies reach those who need them most.
Together, we're turning innovation into impact. Join us in raising awareness and supporting equitable healthcare.

On Maternal Health Awareness Day, January 23, we focus on the delicate balance of risk-benefit in formulations for pregnancy and lactation—where safety is non-negotiable.
At Lyrus, our CDMO expertise shines through rigorous safety profiling, comprehensive documentation per FDA PLLR guidelines (including risk summaries and lactation data), bioequivalence strategies tailored for vulnerable populations, and ongoing dialogues with regulatory authorities. These steps ensure therapies are not just effective but demonstrably safe, minimizing placental/breast milk transfer risks while maximizing maternal outcomes.
Partnering with us means innovation grounded in evidence—protecting mothers and babies, one formulation at a time. Share your insights on safe pharma design below.

On the eve of harvest festivals like and , we reflect on themes of abundance and renewal—just as Lyrus nurtures niche molecules from innovative labs to global markets. Our journey mirrors this cycle: reaping R&D successes through pilot manufacturing and strategic alliances for patient-centric dosage forms.
Our end-to-end CDMO platform takes complex formulations from dedicated research labs to in-house pilot scale, then leverages portability via MHRA/EU GMP/FDA-approved alliances worldwide. This ensures seamless market access in regulated regions like Europe, US, Australia, and Africa, prioritizing innovative, patient-centric dosage forms.​
B2B partners, let's collaborate on your next breakthrough. DM for discussions on NDDS or generics development.

On National Youth Day, India honours the birth anniversary of Swami Vivekananda and celebrates the power of young minds to shape the nation’s future. At Lyrus, this spirit lives in every young scientist, analyst and regulatory professional who is pushing the boundaries of drug delivery, formulation science and quality.
​
From NDDS and controlled release technologies to analytical development and dossier preparation for global markets, our teams demonstrate how empowered youth can convert ideas into impactful healthcare solutions. Their curiosity, courage and commitment are helping build a healthier, more self-reliant India and creating value for patients worldwide.
​
To the next generation of pharma innovators: your skills, integrity and resilience will define the future of global healthcare. Keep learning, keep questioning, and keep building solutions that matter.